However, up to 40% of IBD patients do not respond to initial treatment with anti-TNF agents [primary nonresponse (PNR)], and a similar proportion of patients lose response over time [secondary loss of response (SLR)] after initially achieving clinical remission (Danese et al., 2011; Ben-Horin et al., 2014). Here, TNF is linked to inflammatory bowel disease.